JP6368254B2 - 脂質の網羅的解析方法 - Google Patents
脂質の網羅的解析方法 Download PDFInfo
- Publication number
- JP6368254B2 JP6368254B2 JP2015014637A JP2015014637A JP6368254B2 JP 6368254 B2 JP6368254 B2 JP 6368254B2 JP 2015014637 A JP2015014637 A JP 2015014637A JP 2015014637 A JP2015014637 A JP 2015014637A JP 6368254 B2 JP6368254 B2 JP 6368254B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- ionization
- cholesterol
- lipids
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002632 lipids Chemical class 0.000 title claims description 88
- 238000004458 analytical method Methods 0.000 title claims description 33
- 150000002500 ions Chemical class 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 57
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 42
- 229940106189 ceramide Drugs 0.000 claims description 35
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 33
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 33
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 33
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 33
- 210000000434 stratum corneum Anatomy 0.000 claims description 33
- 238000001514 detection method Methods 0.000 claims description 23
- 235000021588 free fatty acids Nutrition 0.000 claims description 22
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 claims description 21
- 235000012000 cholesterol Nutrition 0.000 claims description 21
- 238000000132 electrospray ionisation Methods 0.000 claims description 21
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims description 20
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims description 20
- 238000004949 mass spectrometry Methods 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 5
- 239000005695 Ammonium acetate Substances 0.000 claims description 5
- 235000019257 ammonium acetate Nutrition 0.000 claims description 5
- 229940043376 ammonium acetate Drugs 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 47
- 210000003491 skin Anatomy 0.000 description 24
- 238000000926 separation method Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000003480 eluent Substances 0.000 description 13
- 238000004364 calculation method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000004811 liquid chromatography Methods 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 239000000945 filler Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000003953 normal phase liquid chromatography Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000003648 hair appearance Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000000752 ionisation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001854 atmospheric pressure photoionisation mass spectrometry Methods 0.000 description 2
- 229940090047 auto-injector Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- -1 skin and hair Chemical class 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- VKOBVWXKNCXXDE-BKDZISOFSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-nonatriacontadeuterioicosanoic acid Chemical compound C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])(=O)O VKOBVWXKNCXXDE-BKDZISOFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- HVYWMOMLDIMFJA-IFAPJKRJSA-N Cholesterol_d7 Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])[C@@]1(C)CC2 HVYWMOMLDIMFJA-IFAPJKRJSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 238000013093 comparative effectiveness research Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 238000000050 ionisation spectroscopy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Description
試料を、逆相液体クロマトグラフィーに供すること;
該クロマトグラフィーに供した試料を、エレクトロスプレーイオン化と大気圧化学イオン化の両方を誘起するマルチイオン源によるイオン化に供すること;ならびに、
該イオン化に供した試料を質量分析にかけて、セラミド、遊離脂肪酸、コレステロール及び硫酸コレステロールを検出すること、
を含む方法を提供する。
試料を、逆相液体クロマトグラフィーに供すること;
該クロマトグラフィーに供した試料を、エレクトロスプレーイオン化と大気圧化学イオン化の両方を誘起するマルチイオン源によるイオン化に供すること;ならびに、
該イオン化に供した試料を質量分析にかけて、セラミド、遊離脂肪酸、コレステロール及び硫酸コレステロールを検出すること、
を含む、方法。
健常男性の前腕及び頬に、フィルムマスキングテープ(寺岡製作所/465#40、2.5cm幅×3cm長)を10秒間押し付けた。この作業を同一箇所で連続3回繰り返すことで皮膚角質層を採取した(採取面積=7.5cm2×3枚)。
角質層を採取したテープを5mLスクリュー管(商品名:マルエム/No.2)内でメタノール溶液1.9mLに浸漬させ、室温で10分間超音波処理し、脂質を抽出した。次いで、このスクリュー管に、内部標準物質混合液〔セラミド群の内部標準物質としてC17:0−Ceramide(Avanti Polar Lipids,Inc.)、遊離脂肪酸群の内部標準物質としてArachidic Acid−d39(Cambridge Isotope Laboratories,Inc.)、コレステロールの内部標準物質としてCholesterol−d7(Avanti Polar Lipids,Inc.)、及び硫酸コレステロールの内部標準物質としてのSodium eicosyl sulfate(Sigma−Aldrich)の混合溶液〕100μLを加え、試料溶液を調製した。
(2)で調製した試料溶液を、下記の条件下でLC−MS分析し、各種脂質(セラミド、遊離脂肪酸、コレステロール及び硫酸コレステロール)の検出及び定量を行った。
(装置)
LC/1100シリーズ、質量分析計/G1956B シングル四重極(Agilent Technologies)
(クロマトグラフィー分離)
分離カラム:L−column ODS 2.1mm内径×150mm、粒径5μm(40℃)
溶離液a:5mmol/L酢酸・10mmol/L酢酸アンモニウム含有メタノール/水=1/1(v/v)
溶離液b:5mmol/L酢酸・10mmol/L酢酸アンモニウム含有2−プロパノール
グラジエント:溶離液b 20%(0min)→20%(1min)→60%(2min)→100%(30min)→100%(35min)
移動相流速:0.2mL/min
平衡化時間:10min
注入量:20μL
(質量分析)
イオン化法:マルチモードイオンソース(ESI/APCI)
極性:正イオン及び負イオン
チャージング電圧:2000V
キャピラリー電圧:2000V(正イオン)、4000V(負イオン)
ベーポライザー温度:200℃
ネブライザー圧力:60psig
乾燥ガス温度:350℃
乾燥ガス流量:4L/min
(検出モード)
セラミド:酢酸イオンが付加された分子([M+CH3COO]-)を負イオンモードでSIM検出
遊離脂肪酸:脱プロトン化分子([M−H]-)を負イオンモードでSIM検出
硫酸コレステロール:金属イオン、又はプロトンイオンが脱離した分子(例えば[M−Na]-)を負イオンモードでSIM検出
コレステロール:プロトン化し脱水された分子([M+H−H2O]+)を正イオンモードでSIM検出
得られたデータを、保持時間とm/zとイオン強度の3軸を有する多段抽出イオンクロマトグラムに展開した。図2の多段抽出イオンクロマトグラムに示されるように、本発明の解析方法により、セラミド、遊離脂肪酸、コレステロール及び硫酸コレステロールが検出された。
10 液体クロマトグラフ
11a、11b グラジエントポンプ
12 オートインジェクター
13 分離カラム
20 質量分析装置
21 イオン化装置
22 質量分離検出装置
30 演算装置
a、b 溶離液
c 試料溶液
Claims (5)
- 試料中の脂質の網羅的解析方法であって、
試料を、逆相液体クロマトグラフィーに供すること;
該クロマトグラフィーに供した試料を、エレクトロスプレーイオン化と大気圧化学イオン化の両方を誘起するマルチイオン源によるイオン化に供すること;ならびに、
該イオン化に供した試料を質量分析にかけて、セラミド、遊離脂肪酸、コレステロール及び硫酸コレステロールを検出すること、
を含む、方法。 - 前記質量分析によるセラミドの検出が負イオンモードで行われる、請求項1記載の方法。
- 前記質量分析による遊離脂肪酸及び硫酸コレステロールの検出が負イオンモードで行われ、コレステロールの検出が正イオンモードで行われる、請求項2記載の方法。
- 前記試料がテープストリッピング法により得られた皮膚角質層の溶媒抽出液である、請求項1〜3のいずれか1項記載の方法。
- 前記イオン化を、酢酸、酢酸アンモニウム、ギ酸及びギ酸アンモニウムからなる群より選択される少なくとも1種のイオン化促進剤の存在下で行う、請求項1〜4のいずれか1項記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015014637A JP6368254B2 (ja) | 2015-01-28 | 2015-01-28 | 脂質の網羅的解析方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015014637A JP6368254B2 (ja) | 2015-01-28 | 2015-01-28 | 脂質の網羅的解析方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016138841A JP2016138841A (ja) | 2016-08-04 |
JP6368254B2 true JP6368254B2 (ja) | 2018-08-01 |
Family
ID=56560182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015014637A Active JP6368254B2 (ja) | 2015-01-28 | 2015-01-28 | 脂質の網羅的解析方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6368254B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183448A1 (en) * | 2017-03-31 | 2018-10-04 | Metabolon, Inc. | Comprehensive and quatitative lipid and tocopherol analysis |
JP7064746B2 (ja) * | 2018-02-14 | 2022-05-11 | 国立大学法人浜松医科大学 | イオン化装置、イオン化方法、プログラム、及び分析システム |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4931369B2 (ja) * | 2005-05-31 | 2012-05-16 | ポーラ化成工業株式会社 | リポソームおよびそれを含む処置用の組成物 |
US20110034419A1 (en) * | 2009-06-27 | 2011-02-10 | Musc Foundation For Research Development | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
CN103597574B (zh) * | 2011-04-20 | 2016-09-07 | 英国质谱公司 | 通过高速喷雾与靶材互相作用的大气压离子源 |
CN103796668B (zh) * | 2011-09-28 | 2016-12-28 | 泰尔茂株式会社 | 含有血红蛋白的脂质体及其制造方法 |
-
2015
- 2015-01-28 JP JP2015014637A patent/JP6368254B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016138841A (ja) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
van Smeden et al. | LC/MS analysis of stratum corneum lipids: ceramide profiling and discovery [S] | |
Hines et al. | Assessment of altered lipid homeostasis by HILIC-ion mobility-mass spectrometry-based lipidomics | |
Zheng et al. | Recent advances in lipid separations and structural elucidation using mass spectrometry combined with ion mobility spectrometry, ion-molecule reactions and fragmentation approaches | |
Ovčačíková et al. | Retention behavior of lipids in reversed-phase ultrahigh-performance liquid chromatography–electrospray ionization mass spectrometry | |
Hancock et al. | Advances and unresolved challenges in the structural characterization of isomeric lipids | |
Pucci et al. | A novel strategy for reducing phospholipids-based matrix effect in LC–ESI-MS bioanalysis by means of HybridSPE | |
Spickett et al. | Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathology | |
Yang et al. | New sample preparation approach for mass spectrometry-based profiling of plasma results in improved coverage of metabolome | |
Brouwers et al. | Rapid separation and identification of phosphatidylethanolamine molecular species | |
Roberts et al. | A matter of fat: an introduction to lipidomic profiling methods | |
Chen et al. | Shotgun lipidomic analysis of human meibomian gland secretions with electrospray ionization tandem mass spectrometry | |
Ismaiel et al. | Monitoring phospholipids for assessment of matrix effects in a liquid chromatography–tandem mass spectrometry method for hydrocodone and pseudoephedrine in human plasma | |
Han et al. | Factors influencing the electrospray intrasource separation and selective ionization of glycerophospholipids | |
Hsu | Complete structural characterization of ceramides as [M− H]− ions by multiple-stage linear ion trap mass spectrometry | |
Jin et al. | Zwitterionic hydrophilic interaction solid-phase extraction and multi-dimensional mass spectrometry for shotgun lipidomic study of Hypophthalmichthys nobilis | |
Wang et al. | Determination of polybrominated diphenyl ethers and novel brominated flame retardants in human serum by gas chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry | |
Sun et al. | Elucidation of phosphatidylcholine isomers using two dimensional liquid chromatography coupled in-line with ozonolysis mass spectrometry | |
Choi et al. | Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma | |
JP5116348B2 (ja) | 被験物質の評価又はスクリーニング方法 | |
Otoki et al. | MS/MS and LC-MS/MS analysis of choline/ethanolamine plasmalogens via promotion of alkali metal adduct formation | |
WO2006092689A1 (en) | Assay of sebum and meibum lipid components by mass spectrometry | |
Gaudin et al. | Ultra performance liquid chromatography–mass spectrometry studies of formalin‐induced alterations of human brain lipidome | |
Shimizu et al. | Mass spectrometric discrimination of squalene monohydroperoxide isomers | |
JP4990010B2 (ja) | 肌質判定方法 | |
Cao et al. | N-alkylpyridinium quaternization combined with liquid chromatography–electrospray ionization-tandem mass spectrometry: A highly sensitive method to quantify fatty alcohols in thyroid tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180612 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180613 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180706 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 6368254 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |